Product Description
Dirocaftor is a type of CFTR modulator called a potentiator.
Mechanisms of Action: CTFR Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yumanity Therapeutics
Company Location:
Company CEO: Richard Peters
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Cystic Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-500410-26-01 |
HIT-CF-001 | P2 |
Active, not recruiting |
Cystic Fibrosis |
2025-06-30 |
2025-05-02 |
||
NCT03251092 |
PTI-808-01 | P2 |
Completed |
Cystic Fibrosis |
2019-12-23 |
43% |
2020-04-23 |
Primary Completion Date |
2017-003319-21 |
2017-003319-21 | P2 |
Completed |
Cystic Fibrosis |
2019-12-23 |
2025-07-06 |
Treatments |
|
NCT03500263 |
PTI-808-02 | P2 |
Completed |
Cystic Fibrosis |
2019-03-13 |
57% |
2019-09-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2022-500410-26-00 |
HIT-CF-001 | P3 |
Withdrawn |
Cystic Fibrosis |
2024-09-30 |
2025-05-02 |
Treatments |